JP2022513566A5 - - Google Patents

Info

Publication number
JP2022513566A5
JP2022513566A5 JP2021517866A JP2021517866A JP2022513566A5 JP 2022513566 A5 JP2022513566 A5 JP 2022513566A5 JP 2021517866 A JP2021517866 A JP 2021517866A JP 2021517866 A JP2021517866 A JP 2021517866A JP 2022513566 A5 JP2022513566 A5 JP 2022513566A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
use according
weight
rpl554
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517866A
Other languages
English (en)
Japanese (ja)
Other versions
JP7578587B2 (ja
JP2022513566A (ja
Filing date
Publication date
Priority claimed from GB1816447.5A external-priority patent/GB2578093B/en
Application filed filed Critical
Publication of JP2022513566A publication Critical patent/JP2022513566A/ja
Publication of JP2022513566A5 publication Critical patent/JP2022513566A5/ja
Priority to JP2024091837A priority Critical patent/JP7836853B2/ja
Application granted granted Critical
Publication of JP7578587B2 publication Critical patent/JP7578587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517866A 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物 Active JP7578587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091837A JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091837A Division JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Publications (3)

Publication Number Publication Date
JP2022513566A JP2022513566A (ja) 2022-02-09
JP2022513566A5 true JP2022513566A5 (cg-RX-API-DMAC7.html) 2022-10-11
JP7578587B2 JP7578587B2 (ja) 2024-11-06

Family

ID=64394831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517866A Active JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物
JP2024091837A Active JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091837A Active JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Country Status (27)

Country Link
US (2) US20210379053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3960157A1 (cg-RX-API-DMAC7.html)
JP (2) JP7578587B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960903B1 (cg-RX-API-DMAC7.html)
CN (1) CN112912064B (cg-RX-API-DMAC7.html)
AU (1) AU2019358585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113167A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124943T1 (cg-RX-API-DMAC7.html)
DK (1) DK3820446T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899744T3 (cg-RX-API-DMAC7.html)
GB (1) GB2578093B (cg-RX-API-DMAC7.html)
HR (1) HRP20220053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057780T2 (cg-RX-API-DMAC7.html)
IL (1) IL282032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3820446T (cg-RX-API-DMAC7.html)
MX (2) MX2021003599A (cg-RX-API-DMAC7.html)
MY (1) MY207302A (cg-RX-API-DMAC7.html)
PH (1) PH12021550767A1 (cg-RX-API-DMAC7.html)
PL (1) PL3820446T3 (cg-RX-API-DMAC7.html)
PT (1) PT3820446T (cg-RX-API-DMAC7.html)
RS (1) RS62775B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102567UA (cg-RX-API-DMAC7.html)
SI (1) SI3820446T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074894A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102039B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Similar Documents

Publication Publication Date Title
JP2022550664A5 (cg-RX-API-DMAC7.html)
HRP20211035T1 (hr) Tekuća formulacija za inhalaciju koja sadrži rpl554
JP2017528479A5 (cg-RX-API-DMAC7.html)
CN102946868B (zh) 包含抗毒蕈碱药的干粉制剂
JP2024113096A5 (cg-RX-API-DMAC7.html)
JP2018199684A (ja) R(+)ブデソニド及び1以上の気管支拡張剤を含む医薬組成物
JP2002537249A (ja) 喘息のためのホルモテロールおよびプロピオン酸フルチカゾンの組み合わせ
SK3892000A3 (en) Use of budesonide and formoterol for producing a composition for the treatment of chronic obstructive pulmonary disease
JP2018505192A5 (cg-RX-API-DMAC7.html)
Pomázi et al. Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam
JP2021522161A5 (cg-RX-API-DMAC7.html)
US20100040691A1 (en) Pharmaceutical compositions comprising methotrexate
KR101668203B1 (ko) 천식의 병세악화를 예방 및/또는 치료하기 위한 포르모테롤 및 베클로메타손 디프로피오네이트를 포함하는 조성의 용도
JP2023516630A5 (cg-RX-API-DMAC7.html)
HUP0303755A2 (hu) Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény
JP2022526367A5 (cg-RX-API-DMAC7.html)
KR102637303B1 (ko) 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
JP2008502699A5 (cg-RX-API-DMAC7.html)
HRP20241621T1 (hr) (1r,3s)-3-((5-cijano-4-feniltiazol-2-il)karbamoil)ciklopentan-1-karboksilna kiselina, namijenjena upotrebi u liječenju bolesti dišnih puteva
RU2021109697A (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
KR102637298B1 (ko) 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
TH2101002047A (th) องค์ประกอบเชิงเภสัชกรรมซึ่งประกอบรวมด้วย rpl554 ใน hfa-134a สำหรับการดำเนินการให้โดยการสูดดม
RU2022103508A (ru) Фармацевтическая композиция, содержащая энсифентрин
JP2022552489A (ja) 肺疾患のための吸入可能な乾燥粉末組成物
NZ767296B2 (en) Liquid Inhalation Formulation Comprising RPL554